menu
    • menu
    [{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Virpax Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Virpax Pharmaceuticals \/ Spartan Capital Securities","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Virpax Pharmaceuticals \/ Spartan Capital Securities","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Virpax Pharmaceuticals \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"NCATS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Virpax Pharmaceuticals \/ NCATS","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ NCATS"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Funding","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Societal CDMO \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Societal CDMO \/ National Institutes of Health"}]

    Find Clinical Drug Pipeline Developments & Deals for Enkephalin

    Menu

    Enkephalin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Spartan Capital Securities

                            Deal Size : $6.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Virpax Closes $6M Public Offering of Common Stock, Pre-Funded Warrants

                            Details : The net proceeds will used to fund the clinical development of Envelta (enkephalin), which is being evaluated for the treatment of neoplasms.

                            Product Name : Envelta

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            January 30, 2025

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Spartan Capital Securities

                            Deal Size : $6.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Spartan Capital Securities

                            Deal Size : $6.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Virpax Prices $6M Public Offering of Common Stock, Pre-Funded Warrants

                            Details : The net proceeds will used to fund the clinical development of Envelta (enkephalin), which is being evaluated for the treatment of neoplasms.

                            Product Name : Envelta

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            January 28, 2025

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Spartan Capital Securities

                            Deal Size : $6.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : NCATS

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Virpax Develops NES100 for Acute and Chronic Pain with HHS Agreement

                            Details : The collaboration aims for the continued development of Virpax’s product candidate, NES100 (leucine enkephalin), an intranasal peptide, for the management of acute and chronic non-cancer pain.

                            Product Name : Envelta

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            November 21, 2024

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : NCATS

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review

                            Details : Envelta (MET-LENK) is a non-addictive intranasal molecular envelope endogenous enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer.

                            Product Name : Envelta

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            October 31, 2023

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)

                            Details : Envelta™ is an intranasal molecular envelope endogenous enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer.

                            Product Name : Envelta

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            February 13, 2023

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Virpax Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic Pain

                            Details : Envelta is an investigational intranasal formulation intended to improve enkephalin transport to the brain. Envelta uses a preassembled device and cartridge to propel the enkephalin formulation through the nose to the brain by flowing along the olfactory...

                            Product Name : Envelta

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            February 10, 2022

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Virpax Advances Envelta™ Development with NCATS Under CRADA Agreement

                            Details : The NIH has contracted with a clinical research organization to conduct additional pre-clinical efficacy studies for Envelta and procured a device to be used with the manufactured GMP drug product for preclinical and clinical studies.

                            Product Name : Envelta

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            November 10, 2021

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Societal CDMO

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Societal CDMO

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel N...

                            Details : Under terms of the new contract, the company will support CMC's of NES-100, a microparticle dosage form of leu-enkephalin (LENK) that is prepared by the encapsulation of LENK in a patent-protected molecular enveloped technology and delivered via a nasal ...

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            October 20, 2021

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Virpax Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : National Center for Advancing Translational Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Virpax to Use Envelta™ IND Enabling Study Results for Two Additional Indications

                            Details : Envelta™ is an investigational intranasal formulation intended to improve enkephalin transport to the brain. Enkephalin is a naturally occurring (endogenous) peptide that is not easily administered in its original form.

                            Product Name : Envelta

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            June 21, 2021

                            Lead Product(s) : Enkephalin

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : National Center for Advancing Translational Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth